Multicenter evaluation of the analytical and clinical performance of the Bayer Immuno 1™ HER-2/neu Assay.

被引：0
|
作者：
Neaman, IE
Goldblatt, JL
Cook, GB
Bruzek, D
Smith, C
Morris, DL
Schwartz, MK
Chan, DW
Allard, WJ
机构：
[1] Bayer Corp, Tarrytown, NY USA
[2] Johns Hopkins Univ Hosp, Div Clin Chem, Baltimore, MD 21287 USA
[3] Mem Sloan Kettering Canc Ctr, Clin Labs, New York, NY 10021 USA
来源：
CLINICAL CHEMISTRY | 2000年 / 46卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
626
引用
收藏
页码：A162 / A162
页数：1
相关论文
共 50 条
  • [21] Evaluation of TECHNICON IMMUNO 1(R) rubella IgM assay.
    Karwowska, S
    Barletta, L
    Lew, F
    Levine, R
    Kang, E
    Jackson, J
    Hinsdale, M
    Bodin, S
    Glover, R
    Dwyer, R
    CLINICAL CHEMISTRY, 1997, 43 : 620 - 620
  • [22] Evaluation of immunohistochemistry and enzyme linked immunosorbent assay for HER-2/neu expression in breast carcinoma
    James R.
    Thriveni K.
    Ramaswamy G.
    Krishnamoorthy L.
    Mukherjee G.
    Vijayalaxmi Deshmane P.P.
    Bapsy P.P.
    Indian Journal of Clinical Biochemistry, 2008, 23 (4) : 345 - 351
  • [23] Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry:: an interlaboratory study assessing the reproducibility of HER-2/NEU testing
    Gancberg, D
    Järvinen, T
    di Leo, A
    Rouas, G
    Cardoso, F
    Paesmans, M
    Verhest, A
    Piccart, MJ
    Isola, J
    Larsimont, D
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (02) : 113 - 120
  • [24] Clinical performance of the Bayer ADVIA® CentaurTM CA 15-3 assay.
    Goldblat, JL
    Santulli, M
    Reamer, CR
    Lin, D
    Schwartz, D
    Morris, DL
    Schwartz, MK
    CLINICAL CHEMISTRY, 2002, 48 (06) : A16 - A16
  • [25] Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing
    David Gancberg
    Tero Järvinen
    Angelo di Leo
    Ghizlane Rouas
    Fatima Cardoso
    Marianne Paesmans
    Alain Verhest
    Martine J. Piccart
    Jorma Isola
    Denis Larsimont
    Breast Cancer Research and Treatment, 2002, 74 : 113 - 120
  • [26] Phase 1 study of infusion of HER-2/neu specific T cells in patients with advanced stage HER-2/neu overexpressing cancers who have received a HER-2/neu vaccine
    Dang, Yushe
    Salazar, Lupe G.
    Coveler, Andrew
    Waisman, James
    Higgins, Doreen
    Childs, Jennifer
    Bates, Nicole
    Slota, Meredith
    Disis, Mary L.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [27] Clinical role of HER-2/neu expression in colorectal cancer
    Pappas, A.
    Lagoudianakis, E.
    Seretis, C.
    Tsiambas, E.
    Koronakis, N.
    Toutouzas, K.
    Katergiannakis, V.
    Manouras, A.
    JOURNAL OF BUON, 2013, 18 (01): : 98 - 104
  • [28] Evaluation of the analytical performance of the Bayer Immuno 1™ and Chiron ACS:180® thyroid panel.
    Despres, N
    Martel, J
    Lachance, JF
    Fink, GD
    Monticello, J
    Grant, AM
    CLINICAL CHEMISTRY, 1998, 44 : A153 - A153
  • [29] Clinical trials of HER-2/neu-specific vaccines
    Murray, JL
    Przepiorka, D
    Ioannides, CG
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 71 - 75
  • [30] Analytical and clinical evaluation of the Bayer ADVIA Centaur homocysteine assay
    Tewari, PC
    Zhang, B
    Conarpe, C
    Bluestein, BI
    CLINICAL CHEMISTRY, 2004, 50 (06) : A6 - A6
12345